Active Biotech AB

Type: Company

Name: Active Biotech AB

Nationality: Sweden

Web Address: http://activebiotech.com/

Fact Sheet: Fact Sheet for Active Biotech AB

First reported Jun 14 2013 - Updated Jun 14 2013 - 2 reports

Phase II

Teva Active Biotech reveal Phase IIa study results of oral laquinimod

Teva Pharmaceutical and Active Biotech have unveiled the results of a Phase IIa study of oral laquinimod in patients with active lupus nephritis. The study is intended to assess safety, tolerability and efficacy in patients suffering from one of the most ... [Published Big News Network - Jun 14 2013]

Entities: Laquinimod, Teva Pharmaceutical Industries Ltd, Active Biotech AB, Systemic Lupus Erythematosus, Phase II

First reported Jun 12 2013 - Updated Jun 12 2013 - 5 reports

Teva Pharmaceutical Industries Ltd

TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS FROM PHASE IIa STUDY OF LAQUINIMOD IN ACTIVE LUPUS NEPHRITIS

I Laquinimod showed additive effect in improving renal function when combined with the standard of care treatment · Results provide rationale for further studies of laquinimod in active lupus nephritis to confirm the safety and efficacy profile observed ... [Published PipelineReview - Jun 12 2013]

Entities: Laquinimod, Systemic Lupus Erythematosus, Lupus Nephritis, Teva Pharmaceutical Industries Ltd

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Active Biotech announces data from Phase II/III renal cell cancer study

Active Biotech, a biotechnology company, has announced overall survival, or OS, and progression free survival, or PFS, data from the ANYARA Phase II/III study in renal cell cancer. The study encompassed 513 patients and was designed to evaluate the effect ... [Published Individual.com - Jun 12 2013]

Entities: ANYARA, Phase II/III, renal cell carcinoma, Active Biotech AB

First reported Jun 03 2013 - Updated Jun 03 2013 - 4 reports

EXINI and Active Biotech AB Present Impact of Tasquinimod on Bone Metastases as Measured by Bone Scan Index (BSI)

EXINI Diagnostics AB (NASDAQ OMX First North: EXINI) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented Phase II retrospective follow-up data from the prostate cancer project with tasquinimod combined with BSI - evaluation (Bone Scan Index) ... [Published BioSpace - Jun 03 2013]

Entities: bone scan, Tasquinimod, bone metastases, Active Biotech AB

First reported Jun 03 2013 - Updated Jun 03 2013 - 6 reports

Active Biotech AB

Active Biotech's Project ANYARA Improved Overall Survival in a Subgroup of Renal Cell Cancer Patients Phase

(live-PR.com) - LUND, SWEDEN -- (Marketwired) -- 06/03/13 -- Active Biotech (NASDAQ OMX NORDIC: ACTI) presented overall survival (OS) and Progression Free Survival (PFS) data the ANYARA Phase II/III study in renal cell cancer at the scientific "2013 ASCO ... [Published Live-PR.com - Jun 03 2013]

Entities: ANYARA, renal cell carcinoma, Active Biotech AB

First reported May 30 2013 - Updated May 30 2013 - 5 reports

Active Biotech to Present at the Jefferies 2013 Global Healthcare Conference

Active Biotech (NASDAQ OMX NORDIC: ACTI) isscheduled to present at the Jefferies 2013 Global Healthcare Conferenceheld June 3-6, 2013 in New York, US. During the presentation, an updateregarding Active Biotech's development programs will be provided.The ... [Published AndhraNews.net - May 30 2013]

Entities: Active Biotech AB, Healthcare Conference, Laquinimod

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Laquinimod Multiple Sclerosis - Forecast and Market Analysis to 2022

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Research and Markets has announced the addition of the "Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022" report to their offering.Teva's and Active Biotech's ... [Published NewsRX - May 24 2013]

Entities: Laquinimod, Multiple Sclerosis, market analysis

First reported Mar 11 2013 - Updated Mar 12 2013 - 1 reports

Active Biotech, Teva complete first patient enrollment in RRMS drug Phase III study

Active Biotech and Teva Pharmaceutical Industries have recruited the first patient in CONCERTO Phase III study of its once-daily oral Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS). ... [Published PBR - News - Mar 11 2013]

Entities: Teva Pharmaceutical Industries Ltd, Active Biotech AB, Phase III

First reported Mar 11 2013 - Updated Mar 11 2013 - 1 reports

Korrigering flaggningsmeddelande i ACTIVE Biotech AB

Anmälan om förvärv av eller överlåtelse av aktier eller depåbevisDetta är en förändring av ett tidigare publicerat flaggningsmeddelande.Emittent 556223-9227 ACTIVE Biotech ABInstrument SE0001137985 ... [Published GlobeNewswire - Mar 11 2013]

Entities: Active Biotech AB, Emitter, Investor AB

First reported Feb 14 2013 - Updated Feb 14 2013 - 1 reports

Active Biotech AB Bokslutsrapport januari - december 2012

Händelser under helåret 2012Laquinimod* fas III-data presenterade på AAN (64th Annual Meeting of the AmericanAcademy of Neurology)* registreringsansökan inlämnad i EU, 5 MUSD i delmålsersättning från Teva* Teva initierar fas III-studie i multipel skleros ... [Published GlobeNewswire - Feb 14 2013]

Entities: Active Biotech AB, Ipsen SA, Laquinimod, Neurology

First reported Dec 23 2012 - Updated Dec 23 2012 - 1 reports

Stockholm Stock Exchange records a solid year

Despite the deep recession in the Eurozone and this fall's strong downturn in the economy, the Stockholm Stock Exchange recorded a great year, with a 12 percent rise in the OMX index. But at 340 points, the exchange is well off its top level of 430 which ... [Published Radio Sweden - Dec 23 2012]

Entities: Stockholm Stock Exchange, Martin Guri, Precise Biometrics AB, Active Biotech AB

Quotes

"The favorable trends towards laquinimod treatment in the renal end-points, coupled with the safety and tolerability profile, provide a rationale for further Phase III clinical studies" said Principal Investigator Dr. David Jayne, Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge

TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS FROM PHASE IIa STUDY OF LAQUINIMOD IN ACTIVE LUPU ... [Published PipelineReview - Jun 12 2013]

Professor Robert Hawkins, the Christie Hospital, Manchester, UK said: "As shown with other immune therapies, patients may be pre-selected using biomarkers to increase their chances to obtain treatment benefits. The results from this study with ANYARA were striking and should be confirmed"

Active Biotech announces data from Phase II/III renal cell cancer study [Published Individual.com - Jun 12 2013]

More From BioPortfolio on "Active Biotech: Active Biotech's project ANYARA improved overall survival in a subgroup of renal cell cancer patients"

Active Biotech Active Biotech's project ANYARA improved overall survival in a subgroup of renal c ... [Published BioPortfolio - Jun 03 2013]

"It's a pretty good return, not the least considering the expectations at the beginning of 2012 and what alternative investments have delivered" says Peter Malmqvist, an independent financial analyst, to news agency TT

Stockholm Stock Exchange records a solid year [Published Radio Sweden - Dec 23 2012]

More Content

sort by: Date \| Relevance
New Lupus Rx Gentler on Kidneys [Published Daily Rx - 19 hours ago]
Teva Active Biotech reveal Phase IIa study resu... [Published Big News Network - Jun 14 2013]
Teva, Active Biotech reveal Phase IIa study res... [Published PBR - News - Jun 14 2013]
TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS... [Published PipelineReview - Jun 12 2013]
Teva reports positive results in Laquinimod lup... [Published Globes - Jun 12 2013]
Teva, Active Biotech Announce Results Of Phase ... [Published RTTNews.com - Jun 12 2013]
TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS... [Published Marketwire - Breaking News Releases - Jun 12 2013]
Teva Pharma (TEVA), Active Biotech Update on La... [Published Street Insider - Jun 12 2013]
TEVA: Study Shows Combined Use of Laquinimod Im... [Published 4 Traders - Jun 12 2013]
TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS... [Published GlobeNewswire: Acquisitions News - Jun 12 2013]
ACTIVE BIOTECH OCH TEVA RAPPORTERAR POSITIVA RE... [Published GlobeNewswire - Jun 12 2013]
Teva and Active Biotech Report Positive Results... [Published Business Wire Health News - Jun 12 2013]
Active Biotech announces data from Phase II/III... [Published Individual.com - Jun 12 2013]
Hormone Refractory (Castration Resistant, Andro... [Published PredictWallStreet - Jun 05 2013]
EXINI and Active Biotech AB Present Impact of T... [Published BioSpace - Jun 03 2013]
Active Biotech's Project ANYARA Improved Overal... [Published Live-PR.com - Jun 03 2013]
Active Biotech Active Biotech's project ANYARA ... [Published BioPortfolio - Jun 03 2013]
Active Biotech AB (BTPC)'s Project ANYARA Impro... [Published BioSpace - Jun 03 2013]
Active Biotech AB Presents Follow-Up Data from ... [Published Reuters - Jun 03 2013]
Active Biotech AB Announces Results of ANYARA P... [Published Reuters - Jun 03 2013]
Impact of Active Biotech's candidate drug tasqu... [Published Marketwire - Breaking News Releases - Jun 03 2013]
Active Biotech's Project ANYARA Improved Overal... [Published Marketwire - Breaking News Releases - Jun 03 2013]
Impact of Active Biotech's candidate drug tasqu... [Published GlobeNewswire: Acquisitions News - Jun 03 2013]
Active Biotech's project ANYARA improved overal... [Published GlobeNewswire: Acquisitions News - Jun 03 2013]
Active Biotechs läkemedelskandidat tasquinimods... [Published GlobeNewswire: Acquisitions News - Jun 03 2013]
Förlängd överlevnad i en subgrupp av njurcancer... [Published GlobeNewswire: Acquisitions News - Jun 03 2013]
EXINI and Active Biotech present impact of tasq... [Published GlobeNewswire: Acquisitions News - Jun 03 2013]
Impact of Active Biotech's candidate drug tasqu... [Published Saudi Fransi Capital - Jun 03 2013]
Active Biotech's project ANYARA improved overal... [Published Saudi Fransi Capital - Jun 03 2013]
Impact of Active Biotech's candidate drug tasqu... [Published NASDAQ OMX - Jun 03 2013]

Blogs

sort by: Date \| Relevance
Teva, Active Biotech reveal Phase IIa study res... [Published PBR - News - Jun 14 2013] Teva Pharmaceutical and Active Biotech have unveiled the results of a Phase IIa study of oral laquinimod in patients with active lupus nephritis. ...
Active Biotech, Teva complete first patient enr... [Published PBR - News - Mar 11 2013] Active Biotech and Teva Pharmaceutical Industries have recruited the first patient in CONCERTO Phase III study of its once-daily oral Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS). ...
Financings of the Fortnight Wonders About The Wolf [Published The IN VIVO Blog - Mar 07 2013] Huffing and puffing and blowing the NIH down?The biggest financial news of the fortnight had to be the U.S. government’s failure to avoid the sequester budget cuts, and the odd collective yawn it produced. Even with the sword of Damocles poised ...

Press Releases

sort by: Date \| Relevance
TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS... [Published Marketwire - Breaking News Releases - Jun 12 2013]
TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS... [Published GlobeNewswire: Acquisitions News - Jun 12 2013]
Teva and Active Biotech Report Positive Results... [Published Business Wire Health News - Jun 12 2013]
Impact of Active Biotech's candidate drug tasqu... [Published Marketwire - Breaking News Releases - Jun 03 2013]
Active Biotech's Project ANYARA Improved Overal... [Published Marketwire - Breaking News Releases - Jun 03 2013]